Welcome back to Healthy Innovations! 🥳

This week we crossed 1,000 subscribers – thank you to everyone who’s read, liked, and shared the newsletter. I’m grateful to have you here, and I hope each week’s deep dive gives you something genuinely useful to take away.

Today we’re looking at innovation in Type 1 diabetes (T1D) – and the steady shift from disruptive finger‑prick testing toward increasingly automated insulin delivery. Over the past decade, continuous glucose monitors and hybrid closed‑loop “artificial pancreas” systems have moved from niche devices into everyday care, quietly taking on much of the minute‑to‑minute decision-making T1D demands.

As the algorithms get better, the trajectory is clear: fewer manual interventions, more time in range, and – for stretches of the day and night – a condition that can recede into the background.

Let’s dive in!

Healthy Innovations has now published 80+ issues – browse the full archive here:

Type 1 diabetes (T1D) is an autoimmune condition in which the body destroys the cells that produce insulin. Without insulin, glucose cannot enter cells. With too much insulin, blood glucose can crash. Managing this becomes a constant math problem – every meal, every walk, every unexpected exertion, every night’s sleep – with no pause and very little margin for error.

Traditional management means doing what a healthy pancreas does quietly and automatically – measuring glucose, estimating carbohydrates, calculating and administering insulin, then waiting and correcting.

A hybrid closed-loop system – the current generation of artificial pancreas technology – takes over much of that work. Three components operate as a single loop:

Together, they do what no human can do reliably overnight – watch the numbers, anticipate trends, and make micro-corrections before a crisis develops.

Sam Wright remembers what nights were like before things changed. Their child, Sofia, was diagnosed with T1D when they were young – and from the first weeks, nighttime became the hardest part of the day. Sam set alarms to check Sofia’s glucose throughout the small hours. If the numbers were off – too low, too high – Sam would give a corrective dose, then lie awake watching and waiting for the reading to move back into safe territory before allowing sleep. Then the alarm would ring again.

Sam was not alone. Fear of nocturnal hypoglycemia is a defining feature of parenting a child with T1D. The dread of blood glucose crashing while a child sleeps and cannot self-correct.

Sam and Sofia were eventually invited to join the KidsAP research trial at the University of Cambridge, testing the CamAPS FX closed-loop system, a hybrid artificial pancreas. Sam’s assessment after the first weeks was straightforward: “I have full trust in the CamAPS FX app and I feel like for the first time since the diagnosis I can relax.”

This technology has moved well beyond proof of concept. The evidence base is substantial, and the results hold across systems, age groups, geographies, and care settings.

A 2022 pivotal trial published in the New England Journal of Medicine tested the iLet Bionic Pancreas from Beta Bionics across 440 adults and children ages 6 and older. The iLet replaces carb counting with a rough meal-size estimate. Over 13 weeks, participants averaged 2.6 additional hours per day in a safe glucose range, with HbA1c dropping by 0.7 percentage points – a clinically meaningful reduction. People using standard care saw no change.

In the UK, a real-world NHS study across eight pediatric diabetes centers tracked 251 children and young people over 12 months. Using three approved hybrid closed-loop systems, including CamAPS FX – the app developed from the Cambridge research that Sam and Sofia participated in – participants achieved a 13.4% average increase in time in range and a 50% reduction in hypoglycemia frequency. This was not a controlled trial. These were children going to school, eating unpredictably, and living ordinary lives.

In Europe, real-world data from more than 100,000 Medtronic MiniMed™ 780G users across Europe, the Middle East and Africa showed a mean time in range of 72.3%, comfortably above the internationally recommended 70% benchmark. In July 2025, the 780G secured a new CE Mark expanding indications to children as young as two, pregnant women, and people with Type 2 diabetes (T2D).

Importantly, the evidence base is not limited to children – the adult data are just as strong.

Four commercially available automated insulin delivery (AID) systems now dominate the field:

The 2026 ADA Standards of Care further strengthen the clinical case, recommending AID alongside CGM as a first-line option for people with T1D.

Today’s hybrid systems still have rough edges– especially around meals and exercise, and during adolescence when hormonal variability can outpace automated delivery.

The next generation is tackling these.

Fully closed-loop systems – requiring no meal announcements at all – have moved from research into real-world clinical trials. The AIDANET trial achieved comparable time in range in free-living adults without any meal input. The FCL@Home study, using neural-network technology, showed fully closed-loop performance exceeding hybrid closed-loop. Algorithms that infer meals from behavioral patterns – removing the last manual step from the loop entirely – are already in development.

Further out is Adocia and its AdoShell device – an implantable capsule of living, insulin-producing beta cells designed to protect them from immune rejection without immunosuppression drugs. First-in-human trials are planned for 2026. The goal is biological restoration – returning insulin production to where it belongs, inside the body.

That future is still years from routine care. For families already living with today’s systems, the transformation is happening now.

For Sofia – and for the millions of people worldwide living with T1D – the shift from manual management to automated delivery is not incremental. It is the difference between a condition managed in the margins of every waking hour and one managed, increasingly, in the background.

🧫 Bioptimus is building what its founders describe as the first general-purpose foundation model for biology – a large-scale AI trained across the full stack of biological data: genomics, transcriptomics, histology, protein structure. The idea is analogous to what large language models did for text: a single pre-trained model that any researcher, drug developer, or diagnostic company can fine-tune for their specific question, rather than building from scratch each time.

Their first public release, H-optimus-0, is an open-weight pathology model trained on whole-slide histology images – already outperforming task-specific models on key benchmarks. The Paris-based team is small, the ambition is not: one model to underpin an entire generation of biological AI applications.

🖌🎨 Blue eyes by appointment only. Francis Ferrari – yes, that's his real name – is a French ophthalmologist who permanently changes the color of your eyes. His procedure, FLAAK, works like this: a femtosecond laser carves a tunnel in each cornea, which is then widened with a surgical hook. Ferrari then uses a scalpel he designed and patented himself to pack pigment into the waiting tissue before painting it with careful brushstrokes. The result? Your eyes, now available in "Riviera blue" or "honey gold."

The American Academy of Ophthalmology has issued two warnings against it, and the FDA hasn't approved it. Ophthalmologists note that even low-grade eye inflammation can cause permanent scarring and chronic light sensitivity. Ferrari remains unmoved. The procedure is as safe as LASIK, he says – and his patients, suffering under the burden of their natural eye color, deserve relief. "There's real suffering," he told the New York Times.

Thank you for reading the Healthy Innovations newsletter!

Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.

Have a great week!

Alison ✨

P.S. If you enjoyed reading the Healthy Innovations newsletter, please subscribe so I know the content is valuable to you!